Alps Advisors Inc Mei Pharma, Inc. Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.42 - $0.65 $57,402 - $88,837	-136,673 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $7,550 - $38,310	-13,982 Reduced 9.28%	136,673 $82,000
Q4 2021 Feb 09, 2022	BUY	$2.33 - $3.37 $29,255 - $42,313	12,556 Added 9.09%	150,655 $402,000
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $25,688 - $30,480	-10,194 Reduced 6.87%	138,099 $381,000
Q2 2021 Aug 11, 2021	SELL	$2.6 - $3.65 $143,735 - $201,782	-55,283 Reduced 27.16%	148,293 $423,000
Q1 2021 May 07, 2021	BUY	$2.73 - $4.5 $5,752 - $9,481	2,107 Added 1.05%	203,576 $698,000
Q4 2020 Feb 03, 2021	BUY	$2.6 - $3.32 $150,724 - $192,463	57,971 Added 40.4%	201,469 $532,000
Q3 2020 Nov 04, 2020	SELL	$2.46 - $4.27 $2,735 - $4,748	-1,112 Reduced 0.77%	143,498 $448,000
Q2 2020 Aug 05, 2020	BUY	$1.45 - $4.3 $209,684 - $621,823	144,610 New	144,610 $597,000
Q2 2019 Aug 07, 2019	SELL	$2.45 - $3.32 $421,037 - $570,548	-171,852 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$2.52 - $3.24 $18,849 - $24,235	7,480 Added 4.55%	171,852 $528,000
Q4 2018 Feb 04, 2019	BUY	$1.92 - $4.1 $315,594 - $673,925	164,372 New	164,372 $434,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $333M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.